CATALYSTChartMill • 3d ago
Pro-Dex (NASDAQ:PDEX) EPS Beat and Margin Expansion Offset In-Line RevenuePro-Dex Q1 EPS beat consensus by 35% while revenue met estimates; gross margin rose to 33% on favorable product mix, lifting shares after hours.
Why PDEX Stock dropped -2.52% Today — RQD Quant Desk Flash
$61.60 -2.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $61.20
Pro-Dex Inc. (PDEX) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $199.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PDEX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Pro-Dex Inc. (NASDAQ: PDEX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $61.60 (-2.52% 1D, market cap $199.2M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PDEX ranks #337 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PDEX compare to KTWO and UTMD in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), PDEX carries a Roarable D (51/100 RQD), trailing P/E of 22.2x, gross margin of 29.3%, and ROIC of 23.2%. By comparison, KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M) and UTMD (Utah Medical Products Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PDEX?
▼
Per PDEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000788920), Pro-Dex Inc. generated $66.6M in revenue (+23.7% YoY), $9.0M in net income, and -$2.9M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $61.21 (-0.64%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PDEX)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY PDEX SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (31% of score)
Altman Z-Score 9.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 29.3% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$62.49-6.8% Next Q
59
Q2 (-2Q)Grade C$58.26+6.8% Next Q
56
Q3 (-1Q)Grade C-$62.22-1% Next Q
54
CurrentGrade D$61.60-1.3% Hist 90D α
51
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PDEX Turnaround Squeeze
While PDEX currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Clean SEC annual filing review with no major hidden accounting time-bombs.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($64.77) and Max Pain ($64.68) forces dealer call-delta covering toward $80.85.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PDEX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PDEX Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PDEX Stock dropped -2.52% Today — RQD Quant Desk Flash
Pro-Dex Inc. (PDEX) dropped -2.52% to $61.60, trading at 68% of its 52-week range ($28.81 – $77). Stretched risk/reward at 22x P/E (23% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 68% of its 52-week range ($28.81 – $77) with RSI-14 at 38.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.6% around $61.60 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 29.3% gross margin and $0 annual free cash flow.
Live PDEX Headlines & Catalysts
MARKET WIREYahoo • 3d ago
Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Surpass EstimatesProDex (PDEX) delivered earnings and revenue surprises of +37.31% and +0.78%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREYahoo • 3d ago
Pro-Dex, Inc. Announces Fiscal 2027 First Quarter ResultsIRVINE, CA / ACCESS Newswire / October 29, 2026 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2027 first quarter ended September 30, 2026.
CATALYSTBenzinga • 3d ago
Pro-Dex Q1 EPS $0.92 Beats $0.66 Estimate, Sales $20.560M Beat $20.400M EstimatePro-Dex (NASDAQ:PDEX) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.66 by 39.39 percent. This is a 34.29 percent decrease over earnings of $1.40 per share from the same
CATALYSTYahoo • 4d ago
Align Technology (ALGN) Beats Q3 Earnings and Revenue EstimatesAlign Technology (ALGN) delivered earnings and revenue surprises of +1.45% and +1.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
CATALYSTYahoo • 4d ago
ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?PDEX heads into fiscal Q1 earnings with strong medical-device sales and margin momentum, but customer concentration, a shrinking backlog and acquisition risks loom.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PDEX)
- ✓Walkthrough of PDEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PDEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.86%▲ ASCENDING CHANNEL
2026-10-30O $63.15H $65.65L $57.62C $61.60VOL 38.5K
RES: $81.73SUP: $56.44SMA50: $64.77SMA200: $56.56
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PDEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
15.9%/yr Implied 5Y Growth
vs. +23.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PDEX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PDEX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PDEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PDEX)
Health Care Rank #337 of 1016
⚔️ KTWO vs PDEX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PDEX vs. KTWO, UTMD, PROF, STIM)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pro-Dex Inc. (PDEX) ranks #337 by composite RQD confidence (51/100, grade D) and #579 by equity capitalization ($199.2M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PDEX at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PDEX
ACTIVE
Pro-Dex Inc. | D | 51/100 | 22.2x | 29.3% | 23.2% | -2.52% | $199.2M | Benchmark Subject |
| KTWO K2 Capital Acquisition Corporation Class A Ordinary Share | D+ | 53/100 | — | — | — | +0.30% | $202.8M | /ktwo-vs-pdex → |
| UTMD Utah Medical Products Inc. | C | 63/100 | — | 57.1% | 26.9% | -2.96% | $212.7M | /utmd-vs-pdex → |
| PROF Profound Medical Corp. | D | 47/100 | — | 70.8% | -35.0% | +1.38% | $214.1M | /prof-vs-pdex → |
| STIM Neuronetics Inc. | E | 31/100 | — | 48.5% | -35.0% | +5.31% | $181.3M | /stim-vs-pdex → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000788920In its most recent audited fiscal period (FY2025, filed 2025-06-30), Pro-Dex Inc. (PDEX) reported GAAP revenue of $66.6M (+23.7% vs. FY2024 revenue of $53.8M , and +44.5% cumulative change since FY2023) , GAAP net income of $9.0M, operating cash flow of -$1.7M, and free cash flow of -$2.9M (-147.0% YoY). On the balance sheet, PDEX closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: 9.08, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $66.6M | $9.0M | -$1.7M | -$2.9M | $62.3M | — |
| FY2024 (FY) | 2024-06-30 | $53.8M | $2.1M | $6.2M | $6.2M | $60.4M | — |
| FY2023 (FY) | 2023-06-30 | $46.1M | $7.1M | $5.5M | $5.5M | — | — |
3. PDEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Pro-Dex Inc. (NASDAQ: PDEX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $61.60 (-2.52% 1D, market cap $199.2M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PDEX ranks #337 in composite RQD confidence.
How does PDEX compare to KTWO and UTMD in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), PDEX carries a Roarable D (51/100 RQD), trailing P/E of 22.2x, gross margin of 29.3%, and ROIC of 23.2%. By comparison, KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M) and UTMD (Utah Medical Products Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PDEX?
Per PDEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000788920), Pro-Dex Inc. generated $66.6M in revenue (+23.7% YoY), $9.0M in net income, and -$2.9M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PDEX trading relative to its 50-day, 200-day, and 52-week technical levels?
PDEX last traded at $61.60 (-2.52% on volume of 43,107 shares), positioning the stock -4.89% below its 50-day simple moving average ($64.77) and +8.91% above its 200-day simple moving average ($56.56). Across its 52-week range of $28.81 to $77.00, PDEX sits at the 68.0% percentile with a 14-day RSI of 38.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($55.69 to $67.51).
PDEX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PDEX stock moving today?
Why PDEX Stock dropped -2.52% Today — RQD Quant Desk Flash. Stretched risk/reward at 22x P/E (23% return on capital) under elevated 10-year interest-rate pressure.